Why the study?
Conventional antiplatelet agents increase bleeding risk by indiscriminately inhibiting thrombosis and hemostasis, and identifying a specific druggable target to block integrin αIIbβ3 outside-in signaling in vivo remains an unproven challenge.
Does DCDBS84 prevent thrombosis without compromising hemostasis in mice?
Population
In vitro and in vivo mouse models
Comparison
DCDBS84 vs high doses of αIIbβ3 antagonist
Design
Preclinical in vitro and in vivo mutational and pharmacological study
Authors
Loading...
May separate antithrombotic efficacy from bleeding risk in mice; leaves open translation of Src SH3 targeting to human therapy.
Does DCDBS84 prevent thrombosis without compromising hemostasis in mice?
DCDBS84 demonstrates that targeting the RT loop of Src SH3 can prevent thrombosis without increasing bleeding risk in preclinical models.
Zhu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: